Earnings To Watch: Zoetis (ZTS) Reports Q4 Results Tomorrow

Animal health company Zoetis (NYSE:ZTS) will be reporting results tomorrow before market open. Here’s what to look for.

Zoetis beat analysts’ revenue expectations by 4.1% last quarter, reporting revenues of $2.39 billion, up 11% year on year. It was a very strong quarter for the company, with a solid beat of analysts’ constant currency revenue estimates.

Is Zoetis a buy or sell going into earnings? Read our full analysis here, it’s free.

This quarter, analysts are expecting Zoetis’s revenue to grow 4.7% year on year to $2.32 billion, slowing from the 8.5% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.34 per share.

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Zoetis has missed Wall Street’s revenue estimates twice over the last two years.

Looking at Zoetis’s peers in the branded pharmaceuticals segment, some have already reported their Q4 results, giving us a hint as to what we can expect. Pfizer delivered year-on-year revenue growth of 21.9%, beating analysts’ expectations by 3%, and Bristol-Myers Squibb reported revenues up 7.5%, topping estimates by 6.6%. Pfizer’s stock price was unchanged after the results, while Bristol-Myers Squibb was down 4.7%.

Read our full analysis of Pfizer’s results here and Bristol-Myers Squibb’s results here.

Investors in the branded pharmaceuticals segment have had steady hands going into earnings, with share prices up 1% on average over the last month. Zoetis is up 5.5% during the same time and is heading into earnings with an average analyst price target of $208.60 (compared to the current share price of $173.52).

When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we’ve found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback.